- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07675252
Efficacy and Safety of Fluticasone Propionate Nebulized Suspension for Wheezing Diseases in Infants Aged 0-24 Months (FPNS-IWD)
A Multicenter Clinical Study on Efficacy and Safety of Fluticasone Propionate Nebulized Suspension in the Treatment of Wheezing Diseases in Infants Aged 0-24 Months
This study looks at how well and how safe fluticasone propionate nebulized suspension works in babies aged 0 to 24 months who have acute wheezing.
Investigators will compare it to budesonide nebulized suspension, another approved inhaled steroid.
About 240 babies will join. Participants will be put into two groups by chance (1:1 randomization):
One group gets fluticasone propionate 0.5 mg twice a day by nebulizer The other group gets budesonide 1 mg twice a day by nebulizer Treatment lasts 5 to 7 days. Investigators will check breathing symptoms (wheezing, cough, phlegm, wheeze sounds in lungs) every day during treatment.
The study will check if fluticasone works as well as budesonide (non-inferiority) and may also check if it works better. Safety will be watched closely, including side effects, general health, and lab tests.
This study will help doctors know if fluticasone propionate nebulized suspension is a good treatment option for young babies with wheezing.
Studienübersicht
Status
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 4
Kontakte und Standorte
Studienkontakt
- Name: Jianguo Hong, Doctor
- Telefonnummer: +86 18730251574
- E-Mail: hongjianguo@hotmail.com
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Age: 0-24 months, gender unlimited;
- Clinical diagnosis: infantile wheezing, with the diagnostic criteria referring to Zhu Futang Practical Pediatrics (9th Edition);
- Inpatients with acute clinical manifestations including wheezing, cough, sputum, and bilateral lung wheezes (wheezing and wheezes are mandatory), and the total score of wheezing symptoms and signs (including wheezing + wheezes) ≥ 2 points;
- The onset of the above wheezing symptoms is within 72 hours;
- The guardian of the subject consents and signs the informed consent form.
Exclusion Criteria:
- Children with a clear diagnosis of congenital heart disease (excluding patent ductus arteriosus or patent foramen ovale), primary immunodeficiency, bronchopulmonary dysplasia, bronchiectasis, foreign bodies in the bronchi, pulmonary tuberculosis, or other congenital malformations that may cause wheezing diseases;
- Those with comorbid primary diseases of the circulatory system, digestive system, urinary system, endocrine system, hematopoietic system, and immune system;
- Those with severe respiratory insufficiency;
- Those allergic to the study drugs;
- Those who have received systemic hormone therapy during the current episode of the disease are not eligible for enrollment;
Before enrollment, any one of the laboratory test indicators meets the following criteria: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) > 2 times the Upper Limit of Normal (ULN) (refer to the normal reference range of laboratory tests in the participating research center); Serum Creatinine (Scr)
- the Upper Limit of Normal.
- Those who have participated in other clinical trials within the past 90 days are not eligible for enrollment;
- Those who the researcher deems unsuitable for participating in the clinical trial are not eligible for enrollment.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: FPN
0.5mg/2ml, BID
|
0.5mg/2ml, BID
|
|
Aktiver Komparator: BUD
1mg/2ml, BID
|
1mg/2ml, BID
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change from baseline in total wheezing symptom score (wheezing, cough, phlegm, wheeze rales) at Day 5 to Day 7
Zeitfenster: From baseline to Day 5 to Day 7 of treatment
|
Change from baseline in total wheezing symptom score (wheezing, cough, phlegm, wheeze rales) at Day 5 to Day 7 Infant Wheezing Symptom and Sign Grading Quantitative Scale, score range: 0-12 points, higher scores indicate more severe wheezing symptoms and signs.
|
From baseline to Day 5 to Day 7 of treatment
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change from baseline in wheezing symptom and sign score (wheezing, cough, sputum, wheeze rales) at 24 hours, 48 hours and Day 3 of treatment
Zeitfenster: From baseline to 24 hours, 48 hours and Day 3 of treatment
|
Change from baseline in wheezing symptom and sign score (wheezing, cough, sputum, wheeze rales) at 24 hours, 48 hours and Day 3 of treatment Infant Wheezing Symptom and Sign Grading Quantitative Scale, score range: 0- 12 points, higher scores indicate more severe wheezing symptoms and signs.
|
From baseline to 24 hours, 48 hours and Day 3 of treatment
|
|
Therapeutic efficacy of wheezing disease at 24 hours, 48 hours, Day 3, Day 5 to Day 7 of treatment
Zeitfenster: From baseline to 24 hours, 48 hours, Day 3, Day 5 to Day 7 of treatment
|
Therapeutic efficacy of wheezing disease at 24 hours, 48 hours, Day 3, Day 5 to Day 7 of treatment. Efficacy is evaluated using an investigator-defined 4-level clinical efficacy scale based on changes in the total score of the Infant Wheezing Symptom and Sign Grading Quantitative Scale (score range: 0-12; higher scores indicate more severe symptoms and signs). Clinical Cure: Complete resolution of clinical symptoms and signs; reduction in total score ≥90%. Marked Improvement: Substantial resolution of clinical symptoms and signs; reduction in total score ≥60% to <90%. Improvement: Partial resolution or improvement of clinical symptoms and signs; reduction in total score ≥30% to <60%. No Improvement: Does not meet the above criteria. Overall Response Rate = (Number of participants with Clinical Cure + Marked Improvement + Improvement) / Total number of participants. |
From baseline to 24 hours, 48 hours, Day 3, Day 5 to Day 7 of treatment
|
|
Length of hospital stay
Zeitfenster: up to 7 days
|
Comparison of hospital stay days
|
up to 7 days
|
|
Usage of combined rescue drugs
Zeitfenster: up to 7 days
|
including the specific drug name, prescribed dosage, detailed administration method and dosage , and specific administration time.
|
up to 7 days
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Hauptermittler: Jianguo Hong, Doctor, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Hauptermittler: Jiujun Li, Doctor, Shengjing Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- FPNS-IWD
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .